From same scammer using different email address:
The Bull Stock Hunter?
From: Ener Sandro Castro Monteblanco (Biologors@hotmail.com)
Sent: Sun 12/13/09 8:56 PM
To: xxxxxxx
Stock News Net
Symbol - FROI
Current - .55
Short Target - 1.35+
Long Target - 3.80+
Rating - 10 of 10
Fero?s aggressive synergistic growth through acquisition strategy for 2010 has already begun with initial negotiations, contact, and current due diligence taking place on two private and five public companies. Fero intends to parlay the Pyro acquisition by blending Pyro?s world class management team and future acquisitions to grow the companies both horizontally and vertically. Don?t miss out on this super gem in the making. The stock is currently trading at the $0.50 level and could be poised to explode as future acquisition targets are announced. With world class management and synergistic acquisitions in the pipeline, Fero (FROI.OB) is a screaming buy for aggressive savvy investors that can connect the dots.
What sets Fero Industries, Inc. (OTCBB: FROI - News) apart from it competitors is the company?s growth through acquisition strategy employs not only acquiring promising new drugs, but also a world class management team and advisors in place to bring the promising new drugs and products to market. FROI?s first acquisition target, market value $12 million, is Pyro Pharmaceuticals, Inc., a boutique developmental stage drug pharmaceutical company located in Irvine, CA. Pyro?s focus is on developing a new class of antibiotics to fight drug resistant bacteria, such as MRSA. Fero intends to parlay the Pyro acquisition by blending Pyro?s world class management team and future acquisitions to grow the companies both horizontally and vertically. The stock is currently trading at the $0.50 level and is poised to explode to the upside as future acquisition targets are announced. Don?t miss out on this super gem in the making.
When we go stock picking, we are in it to win it, and win big. Management is always the most important concern when picking the next 10 bagger stock. Pyro?s management and board members have extensive public company experience and have successfully orchestrated acquisitions and joint ventures with several large, publicly traded medical device and biotechnology companies worth well over $350 million. Deals include Perlegen Sciences, Inc., Memory Pharmaceuticals Corp. sold to Roche, and Cadus Pharmaceutical Corp. whose operations were sold to OSI Pharmaceuticals, Inc. Pyro has also attracted impressive Scientific Advisory Board Members from industry giants such as: Merck, Glaxo, Vertex, Chiron, Abbott, Bristol Myers Squibb, Rhone-Poulenc Rorer, and Hoechst Marion Roussel. Need we say more?
Flying Under The Radar With Stealth Stocks
Send stock manipulators to: enforcement@sec.gov-and to jail.
